arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

XBiotech Inc.

XBIT
$1.89 ▼ -0.06 (-3.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

XBiotech Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $57.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -4.8% ↘
FCF / Share $-0.15 ↗
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-6.73M
↓ -283.1% —
Operating Margin Operating profit as % of sales
-380.3%
↓ -360.6% —
FCF / Share Free cash flow per share
$-0.15
↑ +49.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
22
Financial Health ↓
12
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 52 quarters